Clinical Trial Update: Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating nicotinamide riboside for mitochondrial function in Li-Fraumeni syndrome has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Li-fraumeni Syndrome

Drugs mentioned

• Nicotinamide Riboside (nicotinamide riboside)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Cancer, Skin Fibroblasts | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-12-08